Journal article
Radiopharmaceuticals for Neuroendocrine Tumors
Seminars in radiation oncology, Vol.31(1), pp.60-70
01/01/2021
DOI: 10.1016/j.semradonc.2020.07.007
PMID: 33246637
Abstract
Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that originate in endocrine tissues throughout the body. Peptide receptor radionuclide therapy (PRRT) has emerged as a promising therapeutic option for patients with locally advanced and/or metastatic disease refractory to standard of care treatment. The landmark international phase III NETTER-1 trial led to the approval of Lu-177-DOTATATE (Lutathera) in the treatment of somatostatin receptor-positive gastroenteropancreatic NETs. Similarly, data from the multicenter, phase II Study (IBB)-B-12 led to the approval of meta-[I-131]Iodo-Benzyl-Guanidine ((II)-I-31-MIBG) for treatment of iobenguane scan-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma. With the clinical approval of these novel radiopharmaceuticals for managing select patients with NETs, additional studies are needed to refine patient selection, predict and assess therapy response, and optimize radiopharmaceutical delivery and clinical outcomes. (C) 2020 Elsevier Inc. All rights reserved.y
Details
- Title: Subtitle
- Radiopharmaceuticals for Neuroendocrine Tumors
- Creators
- Re-I Chin - Washington University in St. LouisFrancis S. Wu - Saint Louis UniversityYusuf Menda - University of IowaHyun Kim - Washington University in St. Louis
- Resource Type
- Journal article
- Publication Details
- Seminars in radiation oncology, Vol.31(1), pp.60-70
- Publisher
- Elsevier
- DOI
- 10.1016/j.semradonc.2020.07.007
- PMID
- 33246637
- ISSN
- 1053-4296
- eISSN
- 1532-9461
- Number of pages
- 11
- Grant note
- NIH; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA
- Language
- English
- Date published
- 01/01/2021
- Academic Unit
- Radiology; Radiation Oncology
- Record Identifier
- 9984313073202771
Metrics
8 Record Views